Tristel Dividends - TSTL

Tristel Dividends - TSTL

Buy
Sell
Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Tristel Plc TSTL London Ordinary Share GB00B07RVT99 ORD 1P
  Price Change Price Change % Stock Price Last Trade
20.00 4.08% 510.00 16:20:57
Open Price Low Price High Price Close Price Previous Close
490.00 490.00 510.00 510.00 490.00
more quote information »
Industry Sector
HEALTH CARE EQUIPMENT & SERVICES

Tristel TSTL Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
19/10/2020FinalGBX3.8430/06/201930/06/202019/11/202020/11/202018/12/20206.18
24/02/2020InterimGBX2.3430/06/201930/06/202026/03/202027/03/202030/04/20200
16/10/2019FinalGBX3.530/06/201830/06/201921/11/201922/11/201920/12/20195.54
25/02/2019InterimGBX2.0430/06/201830/06/201928/03/201929/03/201930/04/20190
17/10/2018FinalGBX2.9830/06/201730/06/201815/11/201816/11/201814/12/20184.58
20/02/2018InterimGBX1.630/06/201730/06/201822/03/201823/03/201812/04/20180
19/10/2017FinalGBX2.6330/06/201630/06/201716/11/201717/11/201715/12/20174.03
23/02/2017InterimGBX1.430/06/201630/06/201723/03/201724/03/201713/04/20170
17/10/2016FinalGBX2.1930/06/201530/06/201617/11/201618/11/201616/12/20166.33
21/07/2016SpecialGBX330/06/201530/06/201628/07/201629/07/201605/08/20160
24/02/2016InterimGBX1.1430/06/201530/06/201617/03/201618/03/201601/04/20160
12/10/2015FinalGBX2.1430/06/201430/06/201519/11/201520/11/201518/12/20155.72
18/06/2015SpecialGBX330/06/201430/06/201525/06/201526/06/201506/08/20150
25/02/2015InterimGBX0.5830/06/201430/06/201526/03/201527/03/201513/04/20150
13/10/2014FinalGBX1.2630/06/201330/06/201420/11/201421/11/201419/12/20141.62
03/03/2014InterimGBX0.3630/06/201330/06/201426/03/201428/03/201428/03/20140
14/10/2013FinalGBX0.3230/06/201230/06/201327/11/201329/11/201316/12/20130.4
04/03/2013InterimGBX0.0830/06/201230/06/201327/03/201302/04/201315/04/20130
29/10/2012FinalGBX0.3530/06/201130/06/201214/11/201216/11/201214/12/20120.62
12/03/2012InterimGBX0.2730/06/201130/06/201221/03/201223/03/201213/04/20120
24/10/2011FinalGBX0.1230/06/201030/06/201116/11/201118/11/201116/12/20110.56
14/03/2011InterimGBX0.4430/06/201030/06/201123/03/201125/03/201115/04/20110
18/10/2010FinalGBX1.4130/06/200930/06/201017/11/201019/11/201017/12/20101.83
08/03/2010InterimGBX0.42530/06/200930/06/201017/03/201019/03/201031/03/20100
12/10/2009FinalGBX1.330/06/200830/06/200919/10/200921/11/200919/12/20091.7
16/03/2009InterimGBX0.40501/07/200831/12/200823/03/200925/03/200922/04/20090
06/10/2008FinalGBX1.1730/06/200730/06/200819/10/200821/11/200819/12/20081.55
03/03/2008InterimGBX0.38501/07/200731/12/200712/03/200814/03/200809/04/20080
11/12/2007FinalGBX130/06/200630/06/200714/11/200716/11/200714/12/20071.35
19/02/2007InterimGBX0.3501/07/200631/12/200628/02/200702/03/200710/04/20070
19/10/2006FinalGBX0.7330/06/200530/06/200601/11/200603/11/200601/12/20061
13/02/2006InterimGBX0.2801/07/200531/12/200508/03/200610/03/200606/04/20060
03/10/2005FinalGBX0.530/06/200430/06/200502/11/200504/11/200502/12/20050.5

Top Dividend Posts

DateSubject
02/12/2020
11:31
metis20: hTTps://www.londonstockexchange.com/news-article/TSTL/tristel-wins-aim-growth-business-of-the-year-award/14777598 Very well deserved IMO
02/12/2020
11:29
piedro: Well done Tristel Tristel wins AIM Growth Business of the Year Award Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it has won 'AIM Growth Business of the Year Award' at this year's 2020 AIM Awards, which was held as a digital campaign due to COVID-19, from 30 November to the 2 December 2020. This award recognises Tristel's consistent growth in turnover and profit since its IPO in 2005, which the Company has succeeded in maintaining through this year's trying market conditions. .... ....
25/11/2020
16:32
zimbtrader: Perhaps more towards luck than deliberate timing! Have done this a lot with TSTL and always feel quite sad when I sell them and a bit nervous when I rebuy. I suspect a chance will come in the next few months sub 450.
05/11/2020
16:00
james188: Maybe a number of investors also read the company's Q&A recently published and saw the clear potential for continued growth in a number of markets. In the UK, I can envisage that there may be a repeat drop in medical instrument disinfectant orders from the NHS, as non-urgent procedures are once again suspended, but surface disinfectant demand will hopefully more than compensate, as before. I hope that TSTL continues to underpromise and overdeliver. I think that huge potential remains.
23/10/2020
13:51
james188: I also take the view that ongoing reevaluation of the pros and cons of a share is necessary, particularly when seismic events - such as those we are experiencing at the moment - occur. New products will inevitably appear over time, but it will be a relatively long haul before they are approved by the main regulatory authorities. Look at what TSTL are going through in the US with the FDA for products that have been widely approved in numerous other jurisdictions. After that, health authorities and other consumers have to be persuaded to switch from products that have been heavily scrutinised and approved. Surely it would be easier for one of the bigger players to simply acquire TSTL. That has to be the most likely endgame. The US is not the be-all and end-all, but it is one of the most obvious jurisdictions from which a buyer may emerge. I wonder if that is one of the main reasons that TSTL has decided to really ramp up its approval programmes with both the FDA and the EPA. It is not that long ago - less than twelve months,I believe - that TSTL scaled back the number of products in its FDA programme. At that point, the focus was all about Duo for ultrasound devices. Based on the final results and the supporting presentation earlier this week, it now appears that the US programme is receiving a big push, with a substantially increased supporting budget. Interesting times.
23/10/2020
11:29
mighunter: Piedro, a 2 second search of your post history shows you posting on TSTL as early as 2008 - if not before. Why you ask the basic questions you initially have, when the answers have been freely available to seek in those intervening 12 years, I do not know. So what credible information do you actually possess, leading you to suggest that other companies could already be in the process of adopting similar technology.... and further, what proof do you have of it being maybe in a year. And why now rather than any other point in your 12 year history posting on TSTL, as your argument certainly hasn't come true in that timeframe. If you're going to suggest such speculative hunches, it'll need a better explanation you stating that the dinosaurs are now extinct.
20/10/2020
08:40
mach100: Complete cobblers! International growth is already booming for TSTL. The USA is a huge bonus sure but the length of time it is taking means a huge barrier to entry for others. Biden will I assume be more health care friendly than Top Trump. India is a huge market and will be finalised soon. Yield is only 1.2% but I can plough that back in and grow my holdings. They will have to do something with the cash pile which I think from memory grew 50% to £6 million so there will be a nice return in the way of a special divi at some point. Investor's Chumping more like!
19/10/2020
15:10
zimbtrader: Just published....The dividend timetable is as follows:Ex-Dividend date:19 November 2020Record date:20 November  2020Payment date:18 December 2020 
12/9/2020
17:31
james188: I think that it is a very decent shortlist. TSTL have a very decent shot because of their well timed move into the surface disinfectants market and the way that they responded to the surge in demand earlier this year, which was a real stress test for the business. Whilst I think that TSTL is an excellent business (and it is my largest individual holding by some way), the other contenders also have a decent shout. My personal pick for this year would actually be EKF, which has had an outstanding year and which I expect to produce excellent interim results on Monday. However, it won a gong last year for the Renalytix AI deal (also shortlisted in another category this year), so that lowers its odds winning this year. I also hold EKF, so confirmation bias is a factor.
21/8/2020
16:57
james188: The share price movements on this share are always interesting - and often somewhat puzzling. Anyone who read the TSTL Q&A would have known that TSTL expected to be in a position to start selling product into India in the current financial year, so the approvals announced today are very welcome, but hardly a surprise. I agree with the earlier observation that too much focus has been made about the US opportunity (when there are lots of other markets to go for). That said, the US focus was on high level disinfectants for medical devices - and specifically for ultrasound product (Duo). Again the Q&A responses indicate that TSTL is now looking hard at the surface cleaning and disinfection market in the US, where EPA approval is sufficient. No doubt they would need a new distribution partner other than Parker, but it is an obvious market opportunity and there was virtually no share price reaction. I am still adding.
ADVFN Advertorial
Your Recent History
LSE
TSTL
Tristel
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201204 17:36:10